Table 3.
SBWR results, for the fixed effects and top tumour markers associated breast cancer survival in SEARCH.
| HR | 95% CrIa | MPPIb | Imputed | |
|---|---|---|---|---|
| Fixed parameters | ||||
| Intercept | −7.32 | (−8.07, −6.63) | – | |
| log(beta) Hyperprior SD (σβ) | 0.24 | (0.12, 0.71) | – | |
| Weibull scale | 1.74 | (1.54, 1.96) | – | |
| Number positive nodesc (0, 1, 2–4, 5–9, 10+) |
1.61 | (1.45, 1.79) | 8.4% | |
| Tumour size, mmc (<10, 10–19, 20–29, 30–49, 50+) |
1.26 | (1.09, 1.45) | 3.8% | |
| Tumour gradec (Low, Intermediate, High) |
1.47 | (1.14, 1.89) | 10.5% | |
| Morphology – Ductular | – | – | 0% | |
| Morphology – Lobular | 1.55 | (1.10, 2.16) | – | |
| Morphology – Other | 1.06 | (0.64, 1.68) | – | |
| HER2 | 1.47 | (0.97, 2.18) | 10.8% | |
| Detection by screening | 0.79 | (0.55, 1.11) | 6.1% | |
| Hormone therapy | 2.20 | (1.38, 3.86) | <0.01% | |
| Study entry delay, years | 0.88 | (0.79, 0.98) | 0% | |
| ‘Top’ tumour markers | ||||
| PGRP | 0.86 | (0.80, 0.93) | 0.92 | 5.2% |
| PDCD4O2 | 0.75 | (0.62, 0.89) | 0.84 | 43.2% |
| AURKAP | 1.30 | (1.11, 1.51) | 0.68 | 31.0% |
| CD8P | 0.92 | (0.85, 0.98) | 0.30 | 32.9% |
| GATA3I | 0.80 | (0.68, 0.94) | 0.30 | 41.6% |
| BCL2P | 0.94 | (0.90, 0.98) | 0.26 | 9.0% |
a
Credible Intervals (CrI): For the tumour markers, these were calculated conditional on inclusion in the model.
b
Marginal Posterior Probabilitiy of Inclusion in the model – may be interpreted as the posterior probability an association exists with survival, adjusted for all other covariates in the model.
c
Modelled as ordinal continuous.